Page last updated: 2024-08-03 01:12:56
physalaemin
Description
Physalaemin: An oligopeptide isolated from the skin of Physalaemus fuscumaculatus, a South American frog. It is a typical kinin, resembling SUBSTANCE P in structure and action and has been proposed as a sialagogue, antihypertensive, and vasodilator. [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 14717795 |
| MeSH ID | M0016776 |
Synonyms (13)
| Synonym |
|---|
| NCGC00167275-01 |
| physalaemin |
| 2507-24-6 |
| pglu-ala-asp-pro-asn-lys-phe-tyr-gly-leu-met-nh2 |
| h0t4kv6b9j , |
| unii-h0t4kv6b9j |
| physalemin |
| l-methioninamide, 5-oxo-l-prolyl-l-alanyl-l-.alpha.-aspartyl-l-prolyl-l-asparaginyl-l-lysyl-l-phenylalanyl-l-tyrosylglycyl-l-leucyl- |
| physalaemin [mi] |
| fi-6422 |
| l-methioninamide, 5-oxo-l-prolyl-l-alanyl-l-alpha-aspartyl-l-prolyl-l-asparaginyl-l-lysyl-l-phenylalanyl-l-tyrosylglycyl-l-leucyl- |
| DTXSID501043248 |
| AKOS040744344 |
Research
Studies (245)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 147 (60.00) | 18.7374 |
| 1990's | 65 (26.53) | 18.2507 |
| 2000's | 24 (9.80) | 29.6817 |
| 2010's | 9 (3.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 10 (4.00%) | 6.00% |
| Case Studies | 1 (0.40%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 239 (95.60%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| gamma-aminobutyric acid | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid | human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule | 1987 | 1995 | 33.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| chlorine | | halide anion;
monoatomic chlorine | cofactor;
Escherichia coli metabolite;
human metabolite | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| glycerol | | alditol;
triol | algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hydrogen carbonate | | carbon oxoanion | cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 1979 | 1979 | 45.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| histamine | | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter | 1977 | 1985 | 41.3 | low | 0 | 7 | 0 | 0 | 0 | 0 |
| dihydroxyphenylalanine | | hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative | human metabolite | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| methanol | | alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound | amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite | 1986 | 1990 | 36.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| phosphorylcholine | | phosphocholines | allergen;
epitope;
hapten;
human metabolite;
mouse metabolite | 2006 | 2011 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pyridoxal phosphate | | methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate | coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 1999 | 2000 | 24.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| 2-amino-5-phosphonovalerate | | non-proteinogenic alpha-amino acid | NMDA receptor antagonist | 1993 | 1994 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| sk&f-38393 | | benzazepine;
catechols;
secondary amino compound | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 4-aminopyridine | | aminopyridine;
aromatic amine | avicide;
orphan drug;
potassium channel blocker | 1993 | 1997 | 29.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| 7-nitroindazole | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| bisindolylmaleimide i | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 1983 | 1985 | 40.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| cimetidine | | aliphatic sulfide;
guanidines;
imidazoles;
nitrile | adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 1985 | 1989 | 37.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| dimaprit | | imidothiocarbamic ester | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 1984 | 1989 | 37.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| thiorphan | | N-acyl-amino acid | | 1991 | 1997 | 30.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| ethacrynic acid | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| fenvalerate | | aromatic ether;
carboxylic ester;
monochlorobenzenes | pyrethroid ester acaricide;
pyrethroid ester insecticide | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guaifenesin | | methoxybenzenes | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| guanethidine | | azocanes;
guanidines | adrenergic antagonist;
antihypertensive agent;
sympatholytic agent | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 1-(5-isoquinolinesulfonyl)-2-methylpiperazine | | isoquinolines;
N-sulfonylpiperazine | EC 2.7.11.13 (protein kinase C) inhibitor | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hexamethonium | | quaternary ammonium salt | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 1995 | 2011 | 21.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 1985 | 1993 | 35.7 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 1977 | 1994 | 41.3 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| ketanserin | | aromatic ketone;
organofluorine compound;
piperidines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| mexiletine | | aromatic ether;
primary amino compound | anti-arrhythmia drug | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethylmaleimide | | maleimides | anticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| nicardipine | | benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 1989 | 2010 | 27.0 | low | 0 | 1 | 2 | 1 | 0 | 0 |
| phenoxybenzamine | | aromatic amine | | 1982 | 1988 | 39.5 | low | 0 | 4 | 0 | 0 | 0 | 0 |
| potassium chloride | | inorganic chloride;
inorganic potassium salt;
potassium salt | fertilizer | 1987 | 1999 | 32.7 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid | | arenesulfonic acid;
azobenzenes;
methylpyridines;
monohydroxypyridine;
organic phosphate;
pyridinecarbaldehyde | purinergic receptor P2X antagonist | 1999 | 2000 | 24.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| proglumide | | benzamides;
dicarboxylic acid monoamide;
glutamine derivative;
racemate | anti-ulcer drug;
cholecystokinin antagonist;
cholinergic antagonist;
delta-opioid receptor agonist;
drug metabolite;
gastrointestinal drug;
opioid analgesic;
xenobiotic metabolite | 1986 | 1993 | 34.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 1977 | 1979 | 46.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| ritanserin | | organofluorine compound;
piperidines;
thiazolopyrimidine | antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| suramin | | naphthalenesulfonic acid;
phenylureas;
secondary carboxamide | angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug | 1995 | 2015 | 16.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| terbutaline | | phenylethanolamines;
resorcinols | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| tyramine | | monoamine molecular messenger;
primary amino compound;
tyramines | EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| urethane | | carbamate ester | fungal metabolite;
mutagen | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| corticosterone | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| phentolamine | | imidazoles;
phenols;
substituted aniline;
tertiary amino compound | alpha-adrenergic antagonist;
vasodilator agent | 1977 | 1993 | 39.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 1977 | 1993 | 40.3 | low | 0 | 5 | 2 | 0 | 0 | 0 |
| penicillin g | | penicillin allergen;
penicillin | antibacterial drug;
drug allergen;
epitope | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| dimethylphenylpiperazinium iodide | | N-arylpiperazine;
organic iodide salt;
piperazinium salt;
quaternary ammonium salt | nicotinic acetylcholine receptor agonist | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| lysine | | aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid | algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 1985 | 1985 | 39.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| tubocurarine | | bisbenzylisoquinoline alkaloid | drug allergen;
muscle relaxant;
nicotinic antagonist | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| adenosine diphosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate | fundamental metabolite;
human metabolite | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| galactose | | D-galactose;
galactopyranose | Escherichia coli metabolite;
mouse metabolite | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 1977 | 2001 | 35.0 | low | 0 | 2 | 1 | 1 | 0 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| edetic acid | | ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid | anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| adenosine monophosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate | adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| methacholine chloride | | quaternary ammonium salt | | 1985 | 1987 | 38.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| quinoxalines | | mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thioglycerol | | propane-1,2-diols;
thiol | reducing agent;
vulnerary | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| pyrrolidonecarboxylic acid | | 5-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid | algal metabolite | 1982 | 2003 | 32.2 | low | 0 | 3 | 6 | 1 | 0 | 0 |
| quinuclidines | | quinuclidines;
saturated organic heterobicyclic parent | | 1997 | 2006 | 24.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| indazoles | | indazole | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methysergide | | ergoline alkaloid | | 1988 | 1989 | 35.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| betamethasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| congo red | | bis(azo) compound | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| toluene 2,4-diisocyanate | | toluene meta-diisocyanate | allergen;
hapten | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| amidephrine | | sulfonamide | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| thioflavin t | | organic chloride salt | fluorochrome;
geroprotector;
histological dye | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dithiothreitol | | 1,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol | chelator;
human metabolite;
reducing agent | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| hepes | | HEPES;
organosulfonic acid | | 1985 | 1985 | 39.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| manganese | | elemental manganese;
manganese group element atom | Escherichia coli metabolite;
micronutrient | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| sodium sulfate | | inorganic sodium salt | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| copper sulfate | | metal sulfate | emetic;
fertilizer;
sensitiser | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hexadimethrine bromide | | | | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| vasotocin | | | | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| tetradecanoylphorbol acetate | | acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester | antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| pyrrolidine | | azacycloalkane;
pyrrolidines;
saturated organic heteromonocyclic parent | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| substance p | | peptide | neurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent | 1977 | 2014 | 34.5 | medium | 0 | 88 | 41 | 13 | 2 | 0 |
| impromidine | | | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| enkephalin, methionine | | | | 1980 | 1988 | 40.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| captopril | | alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| mezlocillin | | | | 1980 | 2012 | 37.0 | high | 0 | 27 | 1 | 1 | 1 | 0 |
| atracurium | | diester;
quaternary ammonium ion | muscle relaxant;
nicotinic antagonist | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| fomesafen | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols | agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 1978 | 2002 | 32.0 | low | 0 | 2 | 6 | 1 | 0 | 0 |
| mifepristone | | 3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound | abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| loxiglumide | | organic molecular entity | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| mesulergine | | ergot alkaloid;
sulfamides | antiparkinson drug;
dopamine agonist;
serotonergic antagonist | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 1977 | 1999 | 37.0 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| alpha,beta-methyleneadenosine 5'-triphosphate | | nucleoside triphosphate analogue | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-succinimidyl-3-(4-hydroxyphenyl)propionate | | | | 1984 | 1985 | 39.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| cp 96345 | | | | 1994 | 2002 | 28.1 | low | 0 | 0 | 6 | 1 | 0 | 0 |
| 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole | | ether;
imidazoles;
monomethoxybenzene | TRP channel blocker | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sr 48968 | | | | 1994 | 1996 | 29.3 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| fluorocitrate | | carbonyl compound | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate | | 1,1-diunsubstituted alkanesulfonate | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one | | | | 1993 | 2005 | 26.2 | low | 0 | 0 | 6 | 2 | 0 | 0 |
| fk 888 | | peptide | | 1994 | 1999 | 27.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| senktide | | | | 1993 | 2000 | 28.0 | low | 0 | 0 | 6 | 0 | 0 | 0 |
| sr 140333 | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| gr 73632 | | | | 1993 | 2000 | 28.9 | low | 0 | 0 | 7 | 0 | 0 | 0 |
| substance p, methyl ester- | | | | 1984 | 1993 | 35.7 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| glycerophosphoethanolamine | | phosphoethanolamine;
sn-glycerol 3-phosphates | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| neurokinin a (4-10), beta-ala(8)- | | | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| substance p (5-11), pglu(5)-mephe(8)-megly(9)- | | | | 1986 | 1993 | 34.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| neurokinin a(4-10), tyr(5)-trp(6,8,9)-lys(10)- | | | | 1993 | 2004 | 26.6 | medium | 0 | 0 | 5 | 3 | 0 | 0 |
| l 703606 | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| omega-n-methylarginine | | amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| substance p (4-11), pro(4)-trp(7,9)- | | | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| substance p (5-11) | | | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| substance p, pro(9)- | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| substance p, sar(9)-met(o2)(11)- | | | | 1993 | 2010 | 26.3 | low | 0 | 0 | 8 | 3 | 0 | 0 |
| angiotensin ii | | amino acid zwitterion;
angiotensin II | human metabolite | 1978 | 1990 | 40.8 | low | 0 | 7 | 1 | 0 | 0 | 0 |
| atropine | | | | 1977 | 2010 | 32.7 | low | 0 | 9 | 8 | 1 | 0 | 0 |
| glycogen | | | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| bradykinin | | oligopeptide | human blood serum metabolite;
vasodilator agent | 1976 | 1996 | 39.1 | low | 0 | 6 | 3 | 0 | 0 | 0 |
| oxytocin | | heterodetic cyclic peptide;
peptide hormone | oxytocic;
vasodilator agent | 1977 | 1996 | 37.7 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| inositol 1,4,5-trisphosphate | | myo-inositol trisphosphate | mouse metabolite | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ouabain | | 11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone | anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| nitroarginine | | guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid | | 1995 | 2000 | 26.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| pancuronium | | acetate ester;
steroid ester | cholinergic antagonist;
muscle relaxant;
nicotinic antagonist | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| ryanodine | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| devazepide | | 1,4-benzodiazepinone;
indolecarboxamide | antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| arachidonic acid | | icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid | Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite | 1988 | 1998 | 31.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2005 | 2006 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tetragastrin | | peptidyl amide;
tetrapeptide | anxiogenic;
human metabolite | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| enkephalin, leucine | | pentapeptide;
peptide zwitterion | analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite | 1977 | 1985 | 43.3 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| arginine vasopressin | | vasopressin | cardiovascular drug;
hematologic agent;
mitogen | 1984 | 1987 | 38.3 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| dodecylphosphocholine | | phosphocholines | detergent | 2006 | 2011 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 1983 | 2003 | 30.8 | low | 0 | 3 | 11 | 1 | 0 | 0 |
| thiourea | | one-carbon compound;
thioureas;
ureas | antioxidant;
chromophore | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| ranitidine | | C-nitro compound;
furans;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| glycodeoxycholic acid | | bile acid glycine conjugate | human metabolite | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| neurokinin a (3-10), lysyl(3)-glycyl(8)-r-lactam-leucine(9)- | | | | 1993 | 2003 | 27.7 | medium | 0 | 0 | 2 | 1 | 0 | 0 |
| substance p (4-11), beta-ala(4)-sar(9)-met(02)(11)- | | | | 2006 | 2006 | 18.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline | | naphthalenes;
sulfonic acid derivative | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ovalbumin | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alpha-chymotrypsin | | | | 1964 | 1977 | 53.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| quercetin | | 7-hydroxyflavonol;
pentahydroxyflavone | antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| thromboxane b2 | | thromboxanes B | human metabolite;
mouse metabolite | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| morphine | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic | 1984 | 1987 | 38.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| adp beta s | | | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cp 99994 | | | | 1995 | 1999 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| kallidin | | peptide | | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| neurokinin a | | | | 1984 | 2004 | 31.7 | low | 0 | 13 | 18 | 5 | 0 | 0 |
| neurokinin b | | polypeptide | | 1984 | 2004 | 34.5 | low | 0 | 8 | 2 | 2 | 0 | 0 |
| kn 62 | | piperazines | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dermorphin | | oligopeptide | | 1985 | 1990 | 36.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| litorin | | | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| gr 94800 | | | | 1994 | 1995 | 29.5 | medium | 0 | 0 | 2 | 0 | 0 | 0 |
| bombesin nonapeptide | | | | 1984 | 1984 | 40.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 |
| tetrodotoxin | | azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid | animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker | 1982 | 2010 | 31.7 | low | 0 | 5 | 4 | 2 | 0 | 0 |
| oxalates | | | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| dizocilpine maleate | | maleate salt;
tetracyclic antidepressant | anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist | 2001 | 2004 | 21.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| cyclo(gln-trp-phe-gly-leu-met) | | | | 1993 | 1995 | 30.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| ergoline | | diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| win 51708 | | | | 1997 | 2011 | 20.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| sr 142801 | | | | 1997 | 2000 | 25.3 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| (2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine | | | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sincalide | | oligopeptide | | 1983 | 2000 | 36.0 | low | 0 | 5 | 1 | 0 | 0 | 0 |
| mocetinostat | | aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| men 11420 | | | | 1997 | 2001 | 25.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| g(m1) ganglioside | | alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine;
sialotetraosylceramide | | 1982 | 1984 | 41.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| eledoisin | | peptide | | 1964 | 2004 | 39.6 | high | 0 | 71 | 7 | 1 | 0 | 0 |
| substance p | | | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| substance p | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| phyllomedusin | | | | 1985 | 1985 | 39.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 |
| bufokinin | | | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| calcimycin | | benzoxazole | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| pituitrin | | | | 1981 | 1985 | 40.2 | low | 0 | 4 | 0 | 0 | 0 | 0 |
| cholecystokinin | | | | 1978 | 1999 | 39.8 | low | 0 | 7 | 1 | 0 | 0 | 0 |
| ceruletide | | oligopeptide | diagnostic agent;
gastrointestinal drug | 1976 | 1999 | 42.3 | low | 0 | 8 | 1 | 0 | 0 | 0 |
| gr 82334 | | | | 1992 | 2015 | 25.2 | high | 0 | 0 | 45 | 16 | 4 | 0 |
| nociceptin | | organic molecular entity;
polypeptide | human metabolite;
rat metabolite | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| gastrins | | | | 1978 | 1984 | 43.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| glucagon | | peptide hormone | | 1984 | 1987 | 39.2 | low | 0 | 4 | 0 | 0 | 0 | 0 |
| sauvagine | | | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| iberiotoxin | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ranatensin | | | | 1982 | 1985 | 40.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| septide | | | | 1991 | 2003 | 28.7 | low | 0 | 0 | 5 | 1 | 0 | 0 |
| hylambatin | | | | 1984 | 1991 | 37.4 | high | 0 | 4 | 1 | 0 | 0 | 0 |
| neurotensin | | peptide hormone | human metabolite;
mitogen;
neurotransmitter;
vulnerary | 1977 | 1987 | 44.2 | low | 0 | 5 | 0 | 0 | 0 | 0 |
| substance p, prolyl(2)-tryptophan(7,9)- | | | | 1981 | 1984 | 40.6 | low | 0 | 5 | 0 | 0 | 0 | 0 |
| substance p, pro(2)-phe(7)-trp(9)- | | | | 1984 | 1989 | 38.3 | medium | 0 | 3 | 0 | 0 | 0 | 0 |
| substance p, arg(1)-pro(2)-trp(7),(9)-leunh(2)(11)- | | | | 1983 | 1987 | 39.5 | low | 0 | 4 | 0 | 0 | 0 | 0 |
| gr 71251 | | | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| piperidines | | | | 1994 | 2000 | 27.2 | low | 0 | 0 | 10 | 0 | 0 | 0 |
| vasoactive intestinal peptide | | | | 1978 | 2006 | 35.1 | low | 0 | 5 | 1 | 1 | 0 | 0 |
| pyrethrins | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tan 67 | | | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| caseins | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| muramidase | | | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclic gmp | | 3',5'-cyclic purine nucleotide;
guanyl ribonucleotide | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1978 | 1982 | 44.3 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| guanosine triphosphate | | guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate | Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor | 1987 | 1988 | 36.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| guanylyl imidodiphosphate | | nucleoside triphosphate analogue | | 1985 | 1987 | 38.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| dibutyryl cyclic gmp | | | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Abnormal Deep Tendon Reflex | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Ache | 0 | | 1984 | 2014 | 28.0 | low | 0 | 4 | 0 | 3 | 1 | 0 |
| Acrania | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adjuvant Arthritis | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Air Sickness | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Allodynia | 0 | | 1999 | 2011 | 19.8 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| Alloxan Diabetes | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Anesthesia | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Apnea, Obstructive Sleep | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Argentaffinoma | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Asthma | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Asthma, Bronchial | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Aura | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bladder Disorder, Neurogenic | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bleb | 0 | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood Pressure, High | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bronchial Spasm | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bronchospasm | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of Esophagus | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Cancer of ILEUM | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Cancer of Intestines | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Cancer of Lung | 0 | | 1983 | 1985 | 39.7 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| Carcinoid Tumor | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Carcinoma in Situ | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Carcinoma, Bronchial | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Carcinoma, Bronchogenic | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Carcinoma, Intraepithelial | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Carcinoma, Oat Cell | 0 | | 1983 | 1987 | 39.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| Carcinoma, Small Cell | 0 | | 1983 | 1987 | 39.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| Cocaine Abuse | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cocaine-Related Disorders | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Condition, Preneoplastic | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Constriction, Pathologic | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Constriction, Pathological | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Cystitis | 0 | | 1994 | 2014 | 20.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Dehydration | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Disease Models, Animal | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Electrolytes | 0 | | 1978 | 1979 | 45.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Emesis | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Epilepsy | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Erectile Dysfunction | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Esophageal Neoplasms | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Extravasation of Contrast Media | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypertension | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Impotence | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Inflammation | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Injuries, Spinal Cord | 0 | | 2001 | 2015 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Innate Inflammatory Response | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intestinal Neoplasms | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Lung Neoplasms | 0 | | 1983 | 1985 | 39.7 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| Motion Sickness | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Muscle Contraction | 0 | | 1975 | 2010 | 34.8 | high | 0 | 32 | 16 | 5 | 0 | 0 |
| Muscle Relaxation | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Neural Tube Defects | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pain | 0 | | 1984 | 2014 | 28.0 | low | 0 | 4 | 0 | 3 | 1 | 0 |
| Palsy | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Paralysis | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Precancerous Conditions | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Recrudescence | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Reflex, Abnormal | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Salivary Gland Diseases | 0 | | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Sensitivity and Specificity | 0 | | 1995 | 1996 | 28.3 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| Sleep Apnea, Obstructive | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Spinal Cord Injuries | 0 | | 2001 | 2015 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Urinary Bladder, Neurogenic | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Urinary Incontinence | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Vomiting | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Salivary secretion of inorganic electrolytes.International review of physiology, , Volume: 19, 1979
Modification of salivary duct electrolyte transport in rat and rabbit by physalaemin, VIP, GIP and other enterohormones.Pflugers Archiv : European journal of physiology, , Aug-25, Volume: 376, Issue:1, 1978
Physalaemin-like immunoreactivity from human lung small cell carcinoma: isocratic reversed-phase HPLC analysis of the chemically modified peptide.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, , Volume: 99, 1985
Preneoplasia and neoplasia of the bronchus, esophagus, and colon: the use of markers in determining phenotypes and classification.Monographs in pathology, , Issue:26, 1985
Physalaemin: an amphibian tachykinin in human lung small-cell carcinoma.Science (New York, N.Y.), , Jan-07, Volume: 219, Issue:4580, 1983
Contractile responses induced by physalaemin, an analogue of substance P, in the rat esophagus.European journal of pharmacology, , Feb-25, Volume: 628, Issue:1-3, 2010
Characterization of receptors for two Xenopus gastrointestinal tachykinin peptides in their species of origin.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 370, Issue:1, 2004
Effect of tachykinins on ascending and descending reflex pathway in rat small intestine.Acta pharmacologica Sinica, , Volume: 23, Issue:4, 2002
Substance P release in the feline nucleus tractus solitarius during ergoreceptor but not baroreceptor afferent signaling.Brain research, , Jul-19, Volume: 944, Issue:1-2, 2002
Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats.The Journal of urology, , Volume: 165, Issue:5, 2001
Evidence for the involvement of ATP, but not of VIP/PACAP or nitric oxide, in the excitatory effect of capsaicin in the small intestine.European journal of pharmacology, , Mar-31, Volume: 392, Issue:3, 2000
CCK-mediated response in the activation of 5-HT receptor types in the guinea-pig ileum.Journal of physiology and biochemistry, , Volume: 55, Issue:2, 1999
Involvement of endogenous tachykinins and CGRP in the motor responses produced by capsaicin in the guinea-pig common bile duct.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 360, Issue:3, 1999
Tachykinin NK1 and NK2 receptors mediate non-adrenergic non-cholinergic excitatory neuromuscular transmission in the human ileum.Neuropeptides, , Volume: 31, Issue:3, 1997
Sequential activation of the triple excitatory transmission to the circular muscle of guinea-pig colon.Neuroscience, , Volume: 79, Issue:1, 1997
Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate.The Journal of pharmacology and experimental therapeutics, , Volume: 277, Issue:2, 1996
Evidence that tachykinin NK1 and NK2 receptors mediate non-adrenergic non-cholinergic excitation and contraction in the circular muscle of guinea-pig duodenum.British journal of pharmacology, , Volume: 115, Issue:2, 1995
A further analysis of the contraction induced by activation of cholecystokinin A receptors in guinea pig isolated ileum longitudinal muscle-myenteric plexus.The Journal of pharmacology and experimental therapeutics, , Volume: 270, Issue:2, 1994
Specialization of tachykinin NK1 and NK2 receptors in producing fast and slow atropine-resistant neurotransmission to the circular muscle of the guinea-pig colon.Neuroscience, , Volume: 63, Issue:4, 1994
Highly potent substance P antagonists substituted with beta-phenyl- or beta-benzyl-proline at position 10.European journal of pharmacology, , Jun-13, Volume: 258, Issue:3, 1994
Evidence against a peripheral role of tachykinins in the initiation of micturition reflex in rats.The Journal of pharmacology and experimental therapeutics, , Volume: 264, Issue:3, 1993
Neuromodulation mediated by neurokinin-1 subtype receptors in adult rabbit airways.The American journal of physiology, , Volume: 265, Issue:3 Pt 1, 1993
Spinal effects of selective NK-1 and NK-2 receptor antagonists on bladder motility in anesthetized rats.Regulatory peptides, , Jul-02, Volume: 46, Issue:1-2, 1993
Ascending enteric reflex contraction: roles of acetylcholine and tachykinins in relation to distension and propagation of excitation.The Journal of pharmacology and experimental therapeutics, , Volume: 264, Issue:1, 1993
Effect of the NK-1 receptor antagonist GR 82,334 on reflexly-induced bladder contractions.Life sciences, , Volume: 51, Issue:26, 1992
Occurrence, release, and effects of multiple tachykinins in cat colonic tissues and nerves.Gastroenterology, , Volume: 100, Issue:2, 1991
Contractile effects of substance P and other tachykinins on the mouse isolated distal colon.British journal of pharmacology, , Volume: 96, Issue:3, 1989
Contractile response of canine gallbladder and sphincter of Oddi to substance P and related peptides in vitro.Digestive diseases and sciences, , Volume: 34, Issue:6, 1989
Structure-activity relationship of hylambatin and its fragments as studied in the guinea-pig ileum.The Journal of pharmacy and pharmacology, , Volume: 40, Issue:1, 1988
Contractile response to substance P in isolated smooth muscle strips from the intestinal bulb of the carp (Cyprinus carpio).Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology, , Volume: 89, Issue:2, 1988
Comparison of the responses to the sensory neuropeptides, substance P, neurokinin A, neurokinin B and calcitonin gene-related peptide and to trigeminal nerve stimulation in the iris sphincter muscle of the rabbit.Japanese journal of pharmacology, , Volume: 44, Issue:1, 1987
Luminal tachykinin receptors on canine tracheal epithelium: functional subtyping.Regulatory peptides, , Aug-03, Volume: 18, Issue:2, 1987
Action of the newly discovered mammalian tachykinins, substance K and neuromedin K, on gastroduodenal motility of anesthetized dogs.Regulatory peptides, , Volume: 17, Issue:4, 1987
Substance P and acetylcholine both suppress the same K+ current in dissociated smooth muscle cells.The American journal of physiology, , Volume: 251, Issue:4 Pt 1, 1986
Several methodological improvements for the synthesis of biologically active polypeptides.Biopolymers, , Volume: 25 Suppl, 1986
Neuromuscular blocking agents inhibit receptor-mediated increases in the potassium permeability of intestinal smooth muscle.British journal of pharmacology, , Volume: 86, Issue:4, 1985
Histamine H2 receptor antagonists may modify dog intestinal motility independently of their primary action on the H2 receptors.Pharmacological research communications, , Volume: 17, Issue:3, 1985
Some characterization of the responses to substance P and other tachykinins in rabbit iris sphincter muscle.Japanese journal of pharmacology, , Volume: 37, Issue:2, 1985
Contraction of guinea-pig lung parenchymal strips by substance P and related peptides.Archives internationales de pharmacodynamie et de therapie, , Volume: 278, Issue:2, 1985
Interaction of tachykinins with an adrenergic receptor in the rat urinary bladder.European journal of pharmacology, , Mar-12, Volume: 109, Issue:3, 1985
Tachykinin receptors in smooth muscles: a study with agonists (substance P, neurokinin A) and antagonists.European journal of pharmacology, , Nov-26, Volume: 118, Issue:1-2, 1985
Substance K: a novel mammalian tachykinin that differs from substance P in its pharmacological profile.Life sciences, , Mar-19, Volume: 34, Issue:12, 1984
Are the proposed substance P receptor sub-types, substance P receptors?Life sciences, , Aug-20, Volume: 35, Issue:8, 1984
Comparison of potency of substance P and related peptides on [3H]-acetylcholine release, and contractile actions, in the guinea-pig ileum.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 326, Issue:2, 1984
Undeca- and octa-peptide antagonists for substance P, a study on the guinea pig trachea.European journal of pharmacology, , Mar-23, Volume: 99, Issue:2-3, 1984
The effect of substance P and related peptides on the guinea-pig lung strip.Agents and actions, , Volume: 14, Issue:3-4, 1984
Contractile responses to substance P and related peptides of the isolated muscularis mucosae of the guinea-pig oesophagus.British journal of pharmacology, , Volume: 81, Issue:1, 1984
Parallel bioassay of physalaemin and hylambatin on smooth muscle preparations and blood pressure.The Journal of pharmacy and pharmacology, , Volume: 36, Issue:4, 1984
The pharmacological profile of a substance P (SP) antagonist. Evidence for the existence of subpopulations of SP receptors.Acta physiologica Scandinavica, , Volume: 117, Issue:3, 1983
The determination of dissociation constants for substance P and substance P analogues in the guinea pig ileum by pharmacological procedures.Molecular pharmacology, , Volume: 23, Issue:3, 1983
Pharmacological characterization of four related substance P antagonists.Acta physiologica Scandinavica, , Volume: 116, Issue:2, 1982
Further evidence for multiple tachykinin receptors.European journal of pharmacology, , Dec-17, Volume: 86, Issue:1, 1982
Fading and tachyphylaxis to the contractile effects of substance P in the guinea-pig ileum.European journal of pharmacology, , Jun-16, Volume: 81, Issue:1, 1982
A specific substance P antagonist blocks smooth muscle contractions induced by non-cholinergic, non-adrenergic nerve stimulation.Nature, , Dec-03, Volume: 294, Issue:5840, 1981
Parallel bioassay of physalaemin and kassinin, a tachykinin dodecapeptide from the skin of the African frog Kassina senegalensis.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 311, Issue:1, 1980
Inhibition of caerulein and physalaemin-induced contractions of guinea-pig isolated ileum by non-steroidal antiinflammatory drugs and various steroids and their reversal by prostaglandin E1.Prostaglandins and medicine, , Volume: 1, Issue:5, 1978
Enhancement by physalaemin of the contractions induced by cholinomimetics in the guinea-pig ileum.The Journal of pharmacy and pharmacology, , Volume: 29, Issue:7, 1977
Uperolein and other active peptides in the skin of the Australian leptodactylid frogs Uperoleia and Taudactylus.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 289, Issue:1, 1975
The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide-induced cystitis in rats.World journal of urology, , Volume: 32, Issue:1, 2014
Intrathecal administration of the common carboxyl-terminal decapeptide in endokinin A and endokinin B evokes scratching behavior and thermal hyperalgesia in the rat.Neuroscience letters, , Dec-27, Volume: 410, Issue:3, 2006
Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom.Brain research, , Sep-17, Volume: 1021, Issue:1, 2004
Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate.Japanese journal of pharmacology, , Volume: 86, Issue:3, 2001
Behavioural effects of intrathecally injected tachykinins in rats with peripheral nerve transection.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 336, Issue:6, 1987
Effects of substance P analogues in the rat tail-flick test.European journal of pharmacology, , Feb-24, Volume: 134, Issue:3, 1987
Characterization of spinal actions of four substance P analogues.European journal of pharmacology, , Mar-26, Volume: 110, Issue:1, 1985
Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross desensitization.British journal of pharmacology, , Volume: 82, Issue:2, 1984
Electrocorticographic desynchronization after application of visceral and somatic noxious stimuli in urethane-anesthetized rats: effect of intrathecal administration of tachykinin (NK 1 or NK 2) receptor antagonists.The Journal of pharmacology and experimental therapeutics, , Volume: 276, Issue:1, 1996
Fast atom bombardment mass spectrometry.Methods in enzymology, , Volume: 270, 1996
Pharmacological characterization of GR82334, a tachykinin NK1 receptor antagonist, in the isolated spinal cord of the neonatal rat.European journal of pharmacology, , Jul-25, Volume: 281, Issue:1, 1995
In vitro growth inhibition of human small cell lung cancer by physalaemin.Cancer research, , May-01, Volume: 47, Issue:9, 1987
Physalaemin-like immunoreactivity from human lung small cell carcinoma: isocratic reversed-phase HPLC analysis of the chemically modified peptide.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, , Volume: 99, 1985
Physalaemin: an amphibian tachykinin in human lung small-cell carcinoma.Science (New York, N.Y.), , Jan-07, Volume: 219, Issue:4580, 1983
In vitro growth inhibition of human small cell lung cancer by physalaemin.Cancer research, , May-01, Volume: 47, Issue:9, 1987
Physalaemin-like immunoreactivity from human lung small cell carcinoma: isocratic reversed-phase HPLC analysis of the chemically modified peptide.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, , Volume: 99, 1985
Physalaemin: an amphibian tachykinin in human lung small-cell carcinoma.Science (New York, N.Y.), , Jan-07, Volume: 219, Issue:4580, 1983
Intra-articular administration of tachykinin NK₁ receptor antagonists reduces hyperalgesia and cartilage destruction in the inflammatory joint in rats with adjuvant-induced arthritis.European journal of pharmacology, , Oct-01, Volume: 668, Issue:1-2, 2011
Intrathecal administration of the common carboxyl-terminal decapeptide in endokinin A and endokinin B evokes scratching behavior and thermal hyperalgesia in the rat.Neuroscience letters, , Dec-27, Volume: 410, Issue:3, 2006
Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom.Brain research, , Sep-17, Volume: 1021, Issue:1, 2004
Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate.Japanese journal of pharmacology, , Volume: 86, Issue:3, 2001
The modulatory effect of (+)-TAN-67 on the antinociceptive effects of the nociceptin/orphanin FQ in mice.European journal of pharmacology, , Nov-03, Volume: 383, Issue:3, 1999
Physalaemin-like immunoreactivity from human lung small cell carcinoma: isocratic reversed-phase HPLC analysis of the chemically modified peptide.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, , Volume: 99, 1985
Preneoplasia and neoplasia of the bronchus, esophagus, and colon: the use of markers in determining phenotypes and classification.Monographs in pathology, , Issue:26, 1985
Physalaemin: an amphibian tachykinin in human lung small-cell carcinoma.Science (New York, N.Y.), , Jan-07, Volume: 219, Issue:4580, 1983
The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide-induced cystitis in rats.World journal of urology, , Volume: 32, Issue:1, 2014
Intrathecal administration of the common carboxyl-terminal decapeptide in endokinin A and endokinin B evokes scratching behavior and thermal hyperalgesia in the rat.Neuroscience letters, , Dec-27, Volume: 410, Issue:3, 2006
Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom.Brain research, , Sep-17, Volume: 1021, Issue:1, 2004
Nociception and allodynia/hyperalgesia induced by intrathecal administration of fenvalerate.Japanese journal of pharmacology, , Volume: 86, Issue:3, 2001
Behavioural effects of intrathecally injected tachykinins in rats with peripheral nerve transection.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 336, Issue:6, 1987
Effects of substance P analogues in the rat tail-flick test.European journal of pharmacology, , Feb-24, Volume: 134, Issue:3, 1987
Characterization of spinal actions of four substance P analogues.European journal of pharmacology, , Mar-26, Volume: 110, Issue:1, 1985
Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross desensitization.British journal of pharmacology, , Volume: 82, Issue:2, 1984
Safety/Toxicity (2)
Dosage (9)
| Article | Year |
|---|
CGRP(8-37) and CGRP(32-37) contract the iris sphincter in the rabbit eye: antagonism by spantide and GR82334.
Regulatory peptides, , Nov-19, Volume: 49, Issue:1 | 1993 |
The effect of substance P and related peptides on the guinea-pig lung strip.
Agents and actions, , Volume: 14, Issue:3-4 | 1984 |
Interaction of substance P antagonists with substance P receptors on dispersed pancreatic acini.
Biochimica et biophysica acta, , Jun-19, Volume: 804, Issue:2 | 1984 |
Supersensitivity to substance P and physalaemin in rat salivary glands after denervation or decentralization.
Acta physiologica Scandinavica, , Volume: 115, Issue:4 | 1982 |
Effect of substance P and other tachykinins on arterial pressure in guinea-pigs.
Journal of autonomic pharmacology, , Volume: 5, Issue:1 | 1985 |
Interaction of tachykinins with an adrenergic receptor in the rat urinary bladder.
European journal of pharmacology, , Mar-12, Volume: 109, Issue:3 | 1985 |
NK-1 receptor mediation of neurogenic plasma extravasation in rat skin.
British journal of pharmacology, , Volume: 97, Issue:4 | 1989 |
Comparison of the effects of substance P, neurokinin A, physalaemin and eledoisin in facilitating a nociceptive reflex in the rat.
Brain research, , Aug-27, Volume: 381, Issue:1 | 1986 |
Contraction of guinea-pig lung parenchymal strips by substance P and related peptides.
Archives internationales de pharmacodynamie et de therapie, , Volume: 278, Issue:2 | 1985 |